{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:42:23Z","timestamp":1762954943719},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T00:00:00Z","timestamp":1294617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Methotrexate (MTX), which causes adverse effects, such as liver and\/or renal dysfunction, is the most common disease\u2010modifying antirheumatic drug used for the treatment of rheumatoid arthritis and articular\u2010type juvenile idiopathic arthritis (JIA).<\/jats:p><jats:p>\u2022\u2003Pharmacogenetic studies analysing the MTX pathway genes would aid in the development of more personalized therapy.<\/jats:p><jats:p>\u2022\u2003Results regarding the influence of gene polymorphisms on the toxicity and efficacy of MTX are conflicting, and there are marked differences between racial groups in pharmacogenetics.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003The non\u2010TT genotype at \u03b3\u2010glutamyl hydrolase (<jats:italic>GGH<\/jats:italic>) T16C is associated with a high risk of liver dysfunction due to MTX, even after adjustment for duration of MTX treatment.<\/jats:p><jats:p>\u2022\u2003Longer time interval from disease onset to MTX treatment and rheumatoid factor positivity are associated with lower efficacy of MTX in Japanese patients, as reported previously in Caucasian patients with JIA.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold> We investigated whether several polymorphisms within the methotrexate (MTX) pathway genes were related to the toxicity and efficacy of MTX in 92 Japanese patients with articular\u2010type juvenile idiopathic arthritis (JIA).<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> Eight gene polymorphisms within the MTX pathway genes, namely, <jats:italic>RFC<\/jats:italic>, <jats:italic>BCRP<\/jats:italic>, <jats:italic>MTHFR<\/jats:italic> (two), <jats:italic>FPGS<\/jats:italic>, \u03b3\u2010glutamyl hydrolase (<jats:italic>GGH<\/jats:italic>; two) and <jats:italic>ATIC<\/jats:italic>, were genotyped using TaqMan assays. Liver dysfunction was defined as an increase in alanine transaminase to five times the normal upper limit. Non\u2010responders to MTX were defined as patients refractory to MTX and were therefore treated with biologics.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> The non\u2010TT genotype at <jats:italic>GGH<\/jats:italic> T16C was associated with a high risk of liver dysfunction (<jats:italic>P<\/jats:italic>\u2003=\u20030.028, odds ratio\u2003=\u20036.90, 95% confidence interval 1.38\u201334.5), even after adjustment for the duration of MTX treatment. A longer interval from disease onset to treatment (8.5 and 21.3 months, <jats:italic>P<\/jats:italic>\u2003=\u20030.029) and rheumatoid factor positivity (<jats:italic>P<\/jats:italic>\u2003=\u20030.026, odds ratio\u2003=\u20032.87, 95% confidence interval 1.11\u20137.39) were associated with lower efficacy of MTX.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> The non\u2010TT genotype at <jats:italic>GGH<\/jats:italic> T16C was associated with a high risk of liver dysfunction, presumably because the C allele of <jats:italic>GGH<\/jats:italic> C16T may reduce the activity of GGH. The time interval before MTX treatment and rheumatoid factor positivity were associated with the efficacy of MTX treatment. The pharmacogenetics of the MTX pathway genes affects the toxicity and efficacy of MTX in Japanese JIA patients.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03814.x","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T13:11:26Z","timestamp":1285765886000},"page":"237-243","source":"Crossref","is-referenced-by-count":44,"title":["Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis"],"prefix":"10.1111","volume":"71","author":[{"given":"Masakatsu","family":"Yanagimachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Naruto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Miyamae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Imagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuji","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumpei","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4160-0246-8.50015-2"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-008-0123-3"},{"key":"e_1_2_7_4_2","first-page":"1850","article-title":"Adverse effects of low dose methotrexate therapy in rheumatoid arthritis","volume":"20","author":"McKendry RJ","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200204000-00002"},{"key":"e_1_2_7_6_2","first-page":"1832","article-title":"Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis","volume":"32","author":"Schmeling H","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24087"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.10.3832"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.8.2.141"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20460"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.9.1195"},{"key":"e_1_2_7_12_2","first-page":"390","article-title":"International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty RE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-005-0431-9"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-010-0279-5"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.010611"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22640"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature02168"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4160-0246-8.50016-4"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh621"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-009-0259-9"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03814.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03814.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:57:31Z","timestamp":1697443051000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03814.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,10]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03814.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03814.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,10]]}}}